<DOC>
	<DOC>NCT01677910</DOC>
	<brief_summary>The primary objective of the study is to confirm that at least 1 or more doses of telotristat etiprate compared to placebo is effective in reducing the number of daily bowel movements (BMs) from baseline averaged over the 12-week double-blind portion (Treatment Period) of the trial in patients not adequately controlled by current SSA therapy.</brief_summary>
	<brief_title>TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Histopathologicallyconfirmed, welldifferentiated metastatic neuroendocrine tumor Documented history of carcinoid syndrome and currently experiencing ≥4 bowel movements per day during the Runin period Currently receiving stabledose somatostatin analog (SSA) therapy Minimum dose of LAR or depot SSA therapy Octreotide LAR at 30 mg every 4 weeks Lanreotide Depot at 120 mg every 4 weeks Patients who cannot tolerate SSA therapy at a level indicated above will be allowed to enter at their highest tolerated dose Ability and willingness to provide written informed consent Presence of diarrhea attributed to any condition(s) other than carcinoid syndrome Karnofsky Performance status ≤60% Treatment with any tumor directed therapy, including interferon, chemotherapy, mTOR inhibitors ≤4 weeks prior to Screening, or hepatic embolization, radiotherapy, radiolabelled SSA, and/or tumor debulking ≤12 weeks prior to Screening History of short bowel syndrome (SBS) Clinically significant cardiac arrhythmia, bradycardia, tachycardia that would compromise patient safety or the outcome of the study, or QTcF &gt;450 ms Previous exposure to telotristat etiprate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>